<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928837</url>
  </required_header>
  <id_info>
    <org_study_id>Primus Pharmaceuticals LOA-03P</org_study_id>
    <nct_id>NCT00928837</nct_id>
  </id_info>
  <brief_title>Study of Flavocoxid (Limbrel) Versus Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee</brief_title>
  <official_title>A Double-Blind,Randomized, Placebo Controlled, Parallel Group, Multi-Center Study of Flavocoxid (Limbrel) Versuss Naproxen in Subjects With Moderate-Severe Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Primus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Primus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy and safety of flavocoxid (Limbrel) with
      Naproxen and placebo in OA of the knee.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy, safety, quality of life and economic impact of flavocoxid vs
      naproxen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare the efficacy of 2 doses of flavocoxid with that of naproxen and placebo at 12 weeks</measure>
    <time_frame>3 months</time_frame>
    <description>comparison of short WOMAC and timed walk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to compare the safety of 2 doses of flavocoxid with that of naproxen and placebo at 12 weeks</measure>
    <time_frame>3 months</time_frame>
    <description>Comparison of FS-36, subject tolerability VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to compare the efficacy of 2 doses of flavocoxid with that of naproxen and placebo at 12 weeks</measure>
    <time_frame>6 months</time_frame>
    <description>comparison of short WOMAC and timed walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to compare the safety of 2 doses of flavocoxid with that of naproxen and placebo at 12 weeks</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of FS-36, subject tolerability VAS</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>flavocoxid 250 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medical Food product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antiinflammatory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>flavocoxid 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medical food product</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavocoxid 500 mg</intervention_name>
    <description>flavonoid mixture</description>
    <arm_group_label>flavocoxid 500 mg</arm_group_label>
    <other_name>Limbrel 500 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>non-steroidal anti-inflammatory drug</description>
    <arm_group_label>Naproxen</arm_group_label>
    <other_name>naprosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flavocoxid 250 mg</intervention_name>
    <description>Medical food product</description>
    <arm_group_label>flavocoxid 250 mg</arm_group_label>
    <other_name>Limbrel 250 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Major inclusi√≥n criteria:

          1. Adults of either gender, ages 35-85, in general good health

          2. Diagnosed with OA of the knee, K-L Grade 2-3

          3. History of positive response to NSAID's or COX-2 inhibitors

          4. Able and willing to discontinue other medicinal OA therapies for length of the study
             (subjects may continue low dose aspirin for cardioprotection)

          5. Females of child bearing potential must use acceptable method of birth control

        Major exclusion criteria:

          1. Unwilling or unable to read and sign informed consent document

          2. Pregnant and nursing women

          3. History of severe cardiovascular disease including, but not limited to chronic angina,
             congestive heart failure, uncontrolled hypertension, acute myocardial infarction
             within past year

          4. K-L grade 1 or 4 OA of the target knee

          5. chronic bleeding disorder or present use of anticoagulants

          6. History of upper G-I bleed in the past 5 years

          7. Significant renal disease including nephrotic syndrome, proteinuria &gt;1 gm/24 hrs or
             serum Creatinine &gt;2.0

          8. Any arthritic disease that is or has the potential to affect the knees during the
             course of the study

          9. Any other condition that might confound evaluation of the target joint including, but
             not limited to, bursitis, tendonitis or internal derangement in or about the knee,
             gait disturbances (e.g. mechanical, neurological conditions or disorders of the back),
             fibromyalgia, polyneuropathies, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan J Kivitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Recruiting Altoona Center for Clinical Research 1125 Old Rt 220 North Duncansville PA 16635 Phone 814-693-0300 Fax 814-693-0400</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy S Truitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Recruiting MIMA Century Research Associates 65 E. Nasa Blvd Suite 106 Melbourne FL 32901 Phone 321-723-1203 Fax 321-725-3602</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joy Schechtman, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Valley Arthritis Ltd. 6525 W. Sack Drive Suite 108 Glendale AZ 85308 Phone 623-825-5591 Fax 623-362-9264</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David S Silver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>8691 Wilshire Blvd Suite 301 Beverly Hills CA 90211 phone 310-657-9650 Fax 310-659-2841</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathan Wei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arthritis and Osteoporosis Center of Maryland71 Thomas Johnson Drive Frederick MD 21702 Phone 301-694-5800 Fax 301 694-0187</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norman B Gayliss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2845 Aventura Blvd. Suite 100 Aventura FL 33180 Phone 305-932-4295 Fax 305-932-6335</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A. McLain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2022 Brookwood Medical Center Drive Suite 211 Birmingham AL 35209 Phone 205-877-2555 Fax 205-877-2790</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alan Kivitz MD</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.primusrx.com</url>
    <description>Primus Pharmaceuticals,Inc.</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

